Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 6, 2021; 9(28): 8579-8586
Published online Oct 6, 2021. doi: 10.12998/wjcc.v9.i28.8579
Itraconazole therapy for infant hemangioma: Two case reports
Zhe Liu, Sha Lv, Shuang Wang, Sheng-Ming Qu, Gui-Yun Zhang, Yi-Tong Lin, Lei Yang, Fu-Qiu Li
Zhe Liu, Sha Lv, Shuang Wang, Sheng-Ming Qu, Gui-Yun Zhang, Yi-Tong Lin, Lei Yang, Fu-Qiu Li, Department of Dermatology, The Second Hospital of Jilin University, Changchun 130041, Jilin Province, China
Author contributions: Li FQ provided the case; Liu Z was a major contributor in writing the manuscript; Lv S, Wang S and Qu SM consulted the infants’ parents about other treatment methods; Zhang GY and Lin YT reviewed the relevant literature on itraconazole in the treatment of hemangioma; Lin YT provided daily nursing advice to the infants’ parents; All authors have read and approve the final manuscript.
Informed consent statement: Written informed consent was obtained from the patients’ parents for the publication of this case report.
Conflict-of-interest statement: The authors declared no potential conflicts of interest concerning the research, authorship, and/or publication of this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Fu-Qiu Li, MD, Chief Doctor, Professor, Department of Dermatology, The Second Hospital of Jilin University, No. 218 Ziqiang Road, Nanguan District, Changchun 130041, Jilin Province, China.
Received: May 19, 2021
Peer-review started: May 19, 2021
First decision: June 15, 2021
Revised: July 5, 2021
Accepted: July 19, 2021
Article in press: July 19, 2021
Published online: October 6, 2021

Infantile hemangiomas (IHs) are the most common childhood benign tumors, showing distinctive progression characteristics and outcomes. Due to the high demand for aesthetics among parents of IH babies, early intervention is critical in some cases. β-Adrenergic blockers and corticosteroids are first-line medications for IHs, while itraconazole, an antifungal medicine, has shown positive results in recent years.


In the present study, itraconazole was applied to treat two IH cases. The therapeutic course lasted 80-90 d, during which the visible lesion faded by more than 90%. Moreover, no obvious side effects were reported, and the compliance of the baby and parents was desirable.


Although these outcomes further support itraconazole as an effective therapeutic choice for IHs, large-scale clinical and basic studies are still warranted to improve further treatment.

Keywords: Infant, Hemangiomas, Therapeutics, Itraconazole, Oral, Case report

Core Tip: Infantile hemangiomas (IHs) stand as the most common vascular tumors in infants, mainly due to the disorder of vascular architecture and aberrant proliferation of endothelial cells. Early intervention is critical for restraining lesion growth, reducing the risk of complications, and mitigating psychosocial stress. In the two IH cases listed in the study, oral administration of itraconazole, which was dissolved in milk for 80-90 d, yielded satisfying outcomes, including fading of lesions by more than 90%, few side effects, and desirable compliance of the baby’s parents. Overall, itraconazole has been demonstrated being an effective therapeutic choice for IHs.